Tekla Capital Management LLC continued to hold its stake in ARCA biopharma, Inc. (NASDAQ:ABIO) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 811,227 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Tekla Capital Management LLC owned 6.90% of ARCA biopharma worth $1,988,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Aveo Capital Partners LLC increased its stake in shares of ARCA biopharma by 93.7% in the second quarter. Aveo Capital Partners LLC now owns 93,667 shares of the biopharmaceutical company’s stock worth $225,000 after purchasing an additional 45,322 shares in the last quarter. Institutional investors and hedge funds own 39.07% of the company’s stock.

Shares of ARCA biopharma, Inc. (NASDAQ ABIO) remained flat at $1.15 during mid-day trading on Friday. The company’s stock had a trading volume of 32,381 shares. The stock has a 50-day moving average price of $1.32 and a 200-day moving average price of $2.15. The company’s market cap is $13.51 million. ARCA biopharma, Inc. has a 12 month low of $1.05 and a 12 month high of $3.00.

ARCA biopharma (NASDAQ:ABIO) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter. Equities research analysts expect that ARCA biopharma, Inc. will post ($1.75) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/30/tekla-capital-management-llc-has-1988000-holdings-in-arca-biopharma-inc-abio.html.

About ARCA biopharma

ARCA biopharma, Inc (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF).

Want to see what other hedge funds are holding ABIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARCA biopharma, Inc. (NASDAQ:ABIO).

Receive News & Stock Ratings for ARCA biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma Inc. and related stocks with our FREE daily email newsletter.